Mitteilung

Letzte Einträge:
2022-06-21
15:32
[FZJ-2022-02472] Communication
; ; ; et al
NIMG-17. DISCRIMINATION BETWEEN RADIATION INJURY AND BRAIN METASTASIS RECURRENCE BASED ON TEXTURAL FEATURE ANALYSIS OF FET PET – SUPERIOR TO STANDARD METHODS?
BACKGROUND:Since the differentiation of radiation injury and tumor recurrence using standard MRI alone is difficult, we investigated the potential of textural parameters of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for this issue.METHODS:Forty-seven patients (mean age, 55 ± 11 y) with single or multiple contrast-enhancing brain lesions (n=54) on MRI after radiotherapy of brain metastases (predominantly stereotactic radiosurgery) underwent FET PET in an ECAT EXACT HR+ scanner. VOIs were defined on summed images 20-40 min post-injection by a 3-dimensional auto-contouring process using a tumor-to-brain ratio (TBR) of 1.6. [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
14:56
[FZJ-2022-02466] Communication
; ; ; et al
NIMG-38. NON-INVASIVE PREDICTION OF MGMT PROMOTER METHYLATION USING COMBINED FET PET/MRI RADIOMICS
BACKGROUNDRecently, the Response Assessment in Neuro-Oncology (RANO) Working Group emphasized the additional diagnostic value of amino acid PET in addition to MRI. However, the number of studies using amino acid PET/MRI radiomics is still low. [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
14:42
[FZJ-2022-02465] Communication
; ; ; et al
NIMG-05. THE T2-FLAIR MISMATCH SIGN IN IDH-MUTANT ASTROCYTOMAS - IS THERE AN ASSOCIATION WITH FET PET UPTAKE?
BACKGROUNDThe purpose of this study was (i) to assess the reproducibility of the previously described T2-FLAIR mismatch sign as a highly specific MR imaging marker in non-enhancing IDH-mutant, 1p/19q non-codeleted lower-grade gliomas (LGG) of the WHO grades II or III, and (ii) its association with the uptake of the radiolabeled amino acid O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) in PET to further metabolically characterize that sign, which is currently poorly understood.METHODSConsecutive MRI and dynamic FET PET scans (n=134) from newly diagnosed and neuropathologically confirmed IDH-mutant LGG (n=65) and IDH-wildtype gliomas as control group (n=69) were evaluated by two independent raters to assess presence/absence of the T2-FLAIR mismatch sign as well as FET uptake. Interrater agreement was assessed using Cohen’s kappa (κ), as well as diagnostic performance (i.e., positive/negative predictive value; PPV, NPV) of the T2-FLAIR mismatch sign to identify IDH-mutant astrocytomas.RESULTSIn the LGG group, 13 patients (20%) had a T2-FLAIR mismatch sign, which could be identified with a substantial interrater agreement (κ=0.75). [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
11:22
[FZJ-2022-02462] Communication
; ; ; et al
OS9.6 Diagnosis of pseudoprogression using FET PET radiomics
AbstractBACKGROUNDRadiomics derived from different imaging modalities is gaining increasing interest in the field of neuro-oncology. Besides MRI, amino acid PET radiomics may also improve the to date challenging, clinically relevant diagnostic problem of differentiating pseudoprogression (PsP) from tumor progression (TP) [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
11:19
[FZJ-2022-02460] Communication
; ; ; et al
P14.32 Spatial discrepancies between FET PET and conventional MRI in patients with newly diagnosed glioblastoma
AbstractBACKGROUNDIn patients with glioblastoma, the tissue showing contrast enhancement (CE) in MRI is usually the target for resection or radiotherapy. However, the solid tumor mass typically extends beyond the area of CE [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
11:08
[FZJ-2022-02459] Communication
; ; ; et al
NIMG-79. EARLY TREATMENT RESPONSE ASSESSMENT USING O-(2-18F-FLUOROETHYL)-L-TYROSINE (FET) PET COMPARED TO MRI IN MALIGNANT GLIOMAS TREATED WITH ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY
AbstractBACKGROUNDThe goal of this prospective study was to compare the value of conventional MRI and O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET for response assessment in patients with malignant glioma treated with first-line adjuvant temozolomide chemotherapy (TMZ).METHODSAfter biopsy/resection and completion of radiotherapy with concomitant temozolomide, 34 malignant glioma patients (glioblastoma, n=31; IDH-wildtype anaplastic astrocytoma, n=2; H3K27-mutated midline glioma, n=1) (age range, 20–66 years) were subsequently treated with adjuvant TMZ (5/28). FET-PET scans were performed at baseline and after 10–12 weeks. [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
11:02
[FZJ-2022-02458] Communication
; ; ; et al
P01.014 Spatial correlation of FET uptake and MRI contrast enhancement in newly diagnosed glioblastoma patients prior to treatment
BackgroundA complete glioma resection is known to prolong survival. Contrast enhancement (CE) in MRI is usually the target for resection but the solid tumor mass may extend beyond the area of CE. [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
09:56
[FZJ-2022-02448] Communication
; ; ; et al
P09.26 FET PET radiomics - diagnosis of pseudoprogression in glioblastoma patients based on textural features
AbstractIntroduction: The differentiation of pseudoprogression (PsP) from tumor progression (TP) in glioblastoma patients is difficult on the basis of standard MRI alone. Textural feature analysis as part of the concept of radiomics offers a quantitative method to describe tumor heterogeneity and gains increasing interest in the field of neuro-oncology. [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
09:54
[FZJ-2022-02447] Communication
; ; ; et al
NIMG-82. PREDICTING ISOCITRATE DEHYDROGENASE GENOTYPE IN GLIOMAS USING FET PET RADIOMICS
AbstractBACKGROUNDWe investigated the potential of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET textural features compared with static and dynamic FET PET parameters for preoperative differentiation of IDH-mutated (mut) from IDH-wild type (wt) gliomas.METHODSEighty-four glioma patients underwent dynamic FET PET imaging prior to histological confirmation on a stand-alone PET scanner (56 patients; 31 GBM-wt, 3 GBM-mut, 10 AA-wt, 7 AA-mut, 2 AII-mut, 3 ODGII-mut) or a high-resolution hybrid PET/MR scanner (28 patients; 15 GBM-wt, 2 GBM-mut, 1 AA-wt, 7 AA-mut, 1 ODGIII-mut, 1 AII-wt, 1 AII-mut). The IDH genotype was assessed by immunohistochemistry or direct sequencing (if immunohistochemistry was negative). [...]

Details des Eintrags - Ähnliche Datensätze
2022-06-21
09:36
[FZJ-2022-02446] Communication
; ; ; et al
NIMG-78. FIRST TIME CORRELATION OF FET PET, MRI AND POST-MORTEM WHOLE-BRAIN HISTOPATHOLOGY IN A PROGRESSIVE GLIOBLASTOMA
BACKGROUND Amino acid PET using O-(2-[18F]fluoroethyl)-L-tyrosine (FET) provides important additional information on the extent of viable tumor tissue of glioblastoma compared with MRI. Especially after radiochemotherapy, progression of contrast enhancement in MRI can be equivocal and may represent either true tumor progression or treatment-related changes. [...]

Details des Eintrags - Ähnliche Datensätze